Thoracent

Minimally invasive devices for managing pleural effusions and restoring airway patency to improve quality of life, along with an expanded suite of GI tools.

Learn more about Thoracent

Diagnostics

Developing molecular diagnostic tool that aim to triage lung cancer in patients to identify those in need of immediate care.

Learn more about Diagnostics

Biopsy Tools

Developing a suite of steerable endobronchial instruments to target difficult-to-reach and off-airway nodules.

Learn more about our Biopsy Tools

Leadership

Maverix leadership combines decades of clinical, technical, and operating experience.

Learn more about our leadership

Advisors

The Maverix Medical Advisory Board is comprised of leading pulmonary physicians.

Meet our advisors

Partners

Maverix collaborates with firms that are transforming medtech innovation.

See our partners
Most Recent Article
Fierce Biotech
March 29, 2024

Lung Cancer Startup Maverix Medical Snaps Up Diagnostic Developer Cirrus Bio

Read More
PR Newswire
March 29, 2024
Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer
Read More
Wall Street Journal
November 30, 2023
Startup Ajax Health Extends Medtech Innovation Model to Hologic
Read More

Maverix Diagnostics

Sales Inquiries
Customer Care

About

We are developing a diagnostic test that aims to better clarify which patients are most likely to benefit from either tissue sampling or continued monitoring. This helps focus physician efforts on patients that require more active intervention.

Unique Benefits

Early detection and resection is crucial…
More than half of stage I patients are cured by a single surgery.
Lung nodules are detected in 1/4 of CT scans with few identified as cancer.
because time is the enemy…
Patients often wait months to see a pulmonologist.
Current practice is to diagnose over time, so doctors must wait for the next CT scan to see if a nodule grows.
...and a diagnostic could change everything.
A diagnostic tool that identifies high-risk patients could move them to the front of the line for a biopsy.
This could enable them to begin their treatment regime earlier, which could improve outcomes.